Osteoarthritis - Global Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 28, 2019--
The “Osteoarthritis - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Osteoarthritis - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 18, 19, 2, 44 and 12 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 6 and 7 molecules, respectively.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders).
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- 4P-Pharma SAS
- AbbVie Inc
- Abiogen Pharma SpA
- Ablynx NV
- Akaal Pharma Pty Ltd
- Amgen Inc
- Anterogen Co Ltd
- Arthrogen BV
- AVM Biotechnology LLC
- Axsome Therapeutics Inc
- Bioiberica SAU
- Bone Therapeutics SA
- Can-Fite BioPharma Ltd
- Cellular Biomedicine Group Inc
- Chugai Pharmaceutical Co Ltd
- Corestem Inc
- Cynata Therapeutics Ltd
- Daewoong Pharmaceutical Co Ltd
- Eli Lilly and Co
- Ensol Biosciences Inc
- Evgen Pharma Plc
- Flexion Therapeutics Inc
- Galapagos NV
- Gemphire Therapeutics Inc
- Genequine Biotherapeutics GmbH
- GlaxoSmithKline Plc
- HSRx Group
- I-Mab Biopharma Co Ltd
- InKemia IUCT Group SA
- International Stem Cell Corp
- Jeil Pharmaceutical Co Ltd
- K-Stemcell Co Ltd
- Kang Stem Biotech Co Ltd
- Kolon TissueGene Inc
- Kukje Pharmaceutical Industry Co Ltd
- Lateral Pharma Pty Ltd
- Levolta Pharmaceuticals Inc
- LG Chem Ltd
- Link Health Group
- MediPost Co Ltd
- Medivir AB
- Medytox Inc
- Merck KGaA
- Mesoblast Ltd
- MetrioPharm AG
- Mor Research Applications Ltd
- Nordic Bioscience AS
- Novartis AG
- NovelMed Therapeutics Inc
- Paradigm Biopharmaceuticals Ltd
- and more...
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gqd70u
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005319/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Musculoskeletal Disorders Drugs
KEYWORD: EUROPE NORTH AMERICA CENTRAL AMERICA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/28/2019 06:19 AM/DISC: 05/28/2019 06:19 AM